Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Beyond epiphora: exploring visual comorbidity prevalence and visual acuity in patients with epiphora
Author Affiliations & Notes
  • Ashley Shirriff
    Division of Orbital and Ophthalmic Plastic Surgery, Doheny and Stein Eye Institutes, University of California Los Angeles, Los Angeles, California, United States
  • Maxwell Weng
    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States
  • Sean Ghiam
    Tel Aviv University School of Medicine, Tel Aviv, Tel Aviv, Israel
  • Daniel Rootman
    Division of Orbital and Ophthalmic Plastic Surgery, Doheny and Stein Eye Institutes, University of California Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Ashley Shirriff None; Maxwell Weng None; Sean Ghiam None; Daniel Rootman None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1823. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ashley Shirriff, Maxwell Weng, Sean Ghiam, Daniel Rootman; Beyond epiphora: exploring visual comorbidity prevalence and visual acuity in patients with epiphora. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1823.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with epiphora often report vision-related complaints that impair quality of life. However, it remains unclear if there is an increase in prevalence of visual comorbidities and reduced visual acuity in patients with epiphora. We aimed to evaluate visual comorbidity prevalence as well as visual acuities among people affected by epiphora.

Methods : In this cross-sectional cohort study, patients presenting to a tertiary oculoplastics clinic were surveyed for epiphora-related quality of life. They were classified into two groups: those presenting with epiphora and those without. Patients with visual disturbance were defined as those who responded affirmatively to the question, “Do you experience tearing that leads to blurry vision?”. Patients with epiphora were further classified as obstructive or non-obstructive epiphora based on syringing results. Patients presenting for post-operative care or with a history of ocular or orbital trauma were excluded from analysis. Data regarding visual comorbidities was collected. Outcomes included presence of ≥1 active visual comorbidity, and LogMAR acuity in the worse eye. Wilcoxon and chi-square tests were used for statistical analyses.

Results : The final sample included 205 patients, 128 presented with active epiphora (mean age 66 years, 40% male) and 77 did not (mean age 62 years, 22% male). There were 47 epiphora patients with visual disturbance and 81 without. There was a significantly higher prevalence of ≥1 visual comorbidity in epiphora patients (36.7%) compared to that of controls (16.9%, p=0.002). Mean LogMAR did not differ between epiphora and control patients (0.26±0.43 and 0.19±0.30, p=0.14). Visual comorbidity prevalence significantly differed between epiphora patients with and without visual disturbance (53.2% and 27.2%, p=0.003), while LogMAR did not (0.28±0.44 and 0.26±0.44, p=0.84). Additionally, there was no significant difference in prevalence of non-obstructive epiphora between epiphora patients with and without visual disturbance (59.6% and 43.2%, p=0.07).

Conclusions : Our results are consistent with our hypothesis that patients with epiphora and epiphora-related visual disturbance show higher prevalence of visual comorbidity than their respective counterparts. Interestingly, there was no difference in LogMAR between epiphora patients with and without visual disturbance, despite the former reporting concerns for blurred vision.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×